



Caris Life Sciences to Present Eight Studies Highlighting the Power of AI, Multi-Omics and Precision Medicine at ESMO 2026

October 14, 2026

Eight posters will feature AI-driven approaches to treatment prediction, risk stratification and biomarker discovery advancing precision medicine across multiple cancer types

IRVING, Texas, Oct. 14, 2026 /PRNewswire/ -- [Caris Life Sciences](#)® (NASDAQ: CAI), a leading TechBio company, today announced that researchers from Caris and the Caris Precision Oncology Alliance® (Caris POA) will present eight posters at the European Society for Medical Oncology (ESMO) Congress 2026, taking place October 23-27, 2026, in Madrid, Spain. The research showcases the expanding impact of artificial intelligence, molecular profiling and multimodal data integration in advancing precision oncology across multiple tumor types.



The two Caris-led posters focus on AI-driven treatment prediction and risk stratification in breast cancer, as well as six collaborative investigations conducted with members of the Caris POA. Together, the posters span breast, lung, endometrial, melanoma and immuno-oncology research and demonstrate how comprehensive molecular and clinico-genomic data can reveal novel biological insights and inform more personalized treatment approaches.

"Artificial intelligence is transforming our ability to understand cancer biology and predict therapeutic response on an unprecedented scale," said [James Hamrick MD, MPH](#), Chairman of the Caris POA. "The posters to be presented at ESMO 2026 highlight how the integration of AI, molecular profiling and real-world clinical data can uncover clinically meaningful insights that ultimately help guide more precise treatment decisions for patients."

Caris-Led Studies

Posters:

178P – Caris CapeAI, An Artificial Intelligence Model of ER+ Breast Cancer Response to Capecitabine

Authors: Javier Pascual Lopez, Chen Sun, Miguel J. Gil, et al.

Session: AI for clinical workflows and decision-making

Date and time: Sunday, 25 October 2026, 12:00–12:45 (Madrid time)

217P – Toward Precision Extended Endocrine Therapy in Early HR+ Breast Cancer: Multimodal AI for Risk and Benefit

Stratification

Authors: Eleftherios P. Mamounas, Md Ashequr Rahman, Ming Chen, et al.

Session: AI for clinical workflows and decision-making

Date and time: Sunday, 25 October 2026, 12:00–12:45 (Madrid time)

Caris Precision Oncology Alliance Collaborative Studies

Posters:

3285P – Characterization of G-protein coupled estrogen receptor (GPER) and estrogen receptor in EGFR-mutated NSCLC leading to survival differences

Authors: Robert Hsu, Mercy Kehinde-Ige, Sharon Wu, et al.

Session: Pathology and molecular pathology

Date and time: Friday, 23 October 2026, 15:15–16:00 (Madrid time)

1296P – Genomic Scar–Defined Homologous Recombination Deficiency (HRD) and Tumor Immune Microenvironment in Endometrial Cancer (EC)

Authors: Hiromichi Nakajima, Kenichi Harano, Sharon Wu, et al.

Session: Gynecological cancers

Date and time: Monday, 26 October 2026, 12:00–12:45 (Madrid time)

4395P – A 25-gene T-cell exhaustion signature refines TLS-based prediction of immunotherapy benefit

Authors: Nathan El Ghazzi, Andrew Elliott, George Sledge, et al.

Session: Translational research and biomarkers

Date and time: Friday, 23 October 2026, 15:15–16:00 (Madrid time)

2136P – Site-dependent stromal-mesenchymal reprogramming associated with survival and immunotherapy outcomes in BAP1-mutant uveal melanoma (UM)

Authors: Clara J. Oh, Jingshu Chen, Nishant Gandhi, et al.

Session: Melanoma

Date and time: Saturday, 24 October 2026, 12:00–12:45 (Madrid time)

2681P – Characterization of differences across Organ Site Specific Metastasis in NSCLC by Race/Ethnicity

Authors: Robert Hsu, Nishant Gandhi, Krithika Chennapan, et al.

Session: NSCLC, metastatic

Date and time: Monday, 26 October 2026, 12:00–12:45 (Madrid time)

2686P – RRAS2mt Non-small cell lung cancer (NSCLC) defines a distinct subset of RASmt NSCLC

Authors: Sharon Wu, Hui Jing Hoe, Eleonora Gariazzo, et al.

Session: NSCLC, metastatic

Date and time: Monday, 26 October 2026, 12:00–12:45 (Madrid time)

Research highlights will be available at the Caris booth #1021.

About the Caris Precision Oncology Alliance

The Caris Precision Oncology Alliance® (Caris POA) is a global collaborative network of leading cancer centers, academic institutions, research consortia and healthcare organizations dedicated to advancing precision oncology and biomarker-driven research. Through collaboration and innovative scientific programs, the Caris POA works to improve patient care and further the development of precision medicine.

About Caris Life Sciences

Caris Life Sciences® (Caris) is a leading TechBio company actively developing and commercializing innovative solutions to transform healthcare. Through comprehensive molecular profiling (Whole Genome, Whole Exome and Whole Transcriptome Sequencing), advanced AI and machine learning, Caris has created the large-scale, multimodal clinico-genomic database and computing capability needed to analyze and further unravel the molecular complexity of disease. This convergence of next-generation sequencing, AI and machine learning technologies and high-performance computing provides a differentiated platform for developing the latest generation of advanced precision medicine diagnostic solutions for early detection, diagnosis, monitoring, therapy selection and drug development.

Caris was founded with a vision to realize the potential of precision medicine to improve the human condition. Headquartered in Irving, Texas, Caris has offices in Phoenix, New York, Cambridge (MA), Tokyo, Japan and Basel, Switzerland. Caris or its distributor partners provide services in the U.S. and other international markets.

Forward Looking Statements

This press release contains forward-looking statements, within the meaning of the Private Securities Litigation Reform Act of 1995 and other federal securities laws. All statements other than statements of historical facts contained in this press release are forward-looking statements, including statements regarding our business, solutions, plans, objectives, goals, industry trends, financial outlook and guidance. In some cases, forward-looking statements can be identified by words such as "may," "will," "should," "would," "expect," "plan," "anticipate," "could," "intend," "target," "project," "potential," "contemplate," "believe," "estimate,"

"predict," or "continue" or similar expressions.

You should not rely upon forward-looking statements as predictions of future events. Although we believe that the expectations reflected in these forward-looking statements are reasonable based on information currently available to us, we cannot guarantee that the future results, discoveries, levels of activity, performance or events and circumstances reflected in forward-looking statements will be achieved or occur. Forward-looking statements involve known and unknown risks and uncertainties, some of which are beyond our control. Risks and uncertainties that could cause our actual results to differ materially from those indicated or implied by the forward-looking statements in this press release include, among other things: continued development, performance and commercialization of Caris Detect; developments in the precision medicine industry; our future financial performance, results of operations or other operational results or metrics; development, analytical and clinical validation, timing and performance of future solutions by us and our competitors; commercial market acceptance for our solutions, including acceptance of preventive as well as diagnostic testing paradigms, and our ability to meet resulting demand; the rapidly evolving competitive environment in which we operate; third-party payer reimbursement and coverage decisions related to our solutions; the impact on our future volumes of the continued execution of our strategy to re-align and expand our sales organization; risks related to data management, storage, and processing capabilities and our ability to integrate and deploy artificial intelligence and advanced data analytics technologies; our ability to protect and enhance our intellectual property; regulatory requirements, decisions or approvals (including the timing and conditions thereof) related to our solutions, including our application for New York State Department of Health approval for Caris Assure; reliance on third-party suppliers; risks related to data security, patient privacy, and compliance with healthcare data protection regulations as well as potential cybersecurity threats to our data platforms; our compliance with laws and regulations; the outcome of government investigations and litigation; risks related to our indebtedness; and our ability to hire and retain key personnel as well as risks, uncertainties; and other factors described in the section titled "Risk Factors" and elsewhere in our Annual Report on Form 10-K filed on March 3, 2026, and in our other filings we make with the SEC from time to time. We undertake no obligation to update any forward-looking statements to reflect changes in events, circumstances or our beliefs after the date of this press release, except as required by law.

Caris Life Sciences Media:

Corporate Communications

CorpComm@CarisLS.com

214.294.5606

 View original content to download multimedia: <https://www.prnewswire.com/news-releases/caris-life-sciences-to-present-eight-studies-highlighting-the-power-of-ai-multi-omics-and-precision-medicine-at-esmo-2026-302907922.html>

SOURCE Caris Life Sciences